Triana Biomedicines

What Triana Biomedicines does

Triana Biomedicines is a venture-backed, clinical-stage biopharmaceutical company developing targeted protein degradation (TPD) therapies through a proprietary molecular glue discovery platform. Founded in 2021 and headquartered in Lexington, Massachusetts, the company applies a target-first and rational approach that evaluates over 600 known E3 ubiquitin ligases against disease-relevant targets, using a protein:protein pairing engine, high-resolution structural insights, AI/computational tools, and bespoke chemical libraries to identify small molecules that promote protein-protein interactions and selectively degrade disease-causing proteins. Its stated focus is the approximately 85% of disease targets considered undruggable by traditional small-molecule or biologic modalities.

The company's pipeline is led by TRI-611, an oral, brain-penetrant, molecular glue degrader that targets ALK fusion proteins in ALK-positive non-small cell lung cancer (ALK+ NSCLC) through a mechanism independent of the ALK kinase active site, designed to overcome resistance to existing tyrosine kinase inhibitors. TRI-611 entered a global Phase 1/2 first-in-human trial in March 2026 and received U.S. FDA Fast Track designation the same month for patients who have failed two or more ALK TKIs. A second program targets cyclin E1 (CCNE1) for CCNE1-amplified tumors and a subset of HR+/HER2- breast cancers and remains preclinical.

Triana operates a capital- and collaboration-driven business model. The company is pre-revenue on a product basis and instead earns upfront payments, milestone payments, and royalties through strategic research collaborations and licensing agreements with large pharmaceutical partners, notably Pfizer ($49 million upfront plus potential milestones exceeding $1.5 billion and tiered royalties, signed October 2024) and Johnson & Johnson (research collaboration signed January 2026). Since inception Triana has raised approximately $279 million across seed, Series A ($110 million in April 2022), Series B ($120 million in December 2025), and the Pfizer upfront, with a top-tier investor syndicate including RA Capital, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, Ascenta Capital, and Bessemer Venture Partners. The company plans to advance proprietary assets toward proof-of-concept and to pursue either partnership-based or independent commercialization for approved products.

Name

Triana Biomedicines

Legal name

Triana Biomedicines, Inc.

Website

https://trianabio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Triana Biomedicines is a clinical-stage biopharmaceutical company developing molecular glue degraders that selectively eliminate disease-causing proteins, with lead asset TRI-611 in Phase 1/2 trials for ALK-positive NSCLC and additional programs targeting CCNE1-amplified tumors, serving patients with cancers resistant to existing therapies.

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Molecular glue discovery
• Targeted protein degradation
• Cancer therapeutics development
• E3 ligase platform
• Biopharmaceutical research

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Strategic collaborations and licensing (milestone and royalty payments): TRIANA earns upfront payments, milestone payments, and royalties through strategic research collaborations and licensing agreements with pharmaceutical partners. The Pfizer collaboration includes a $49 million upfront payment with potential future milestone payments exceeding $1.5 billion plus tiered royalties. This represents a primary revenue model for the company as a platform-focused biotech.
2. Upfront collaboration payments:
3. Future product commercialization:

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Triana Biomedicines operates a target-first molecular glue discovery platform that systematically identifies small molecules promoting protein-protein interactions to harness the cell's ubiquitin-proteasome system for targeted protein degradation. The company develops proprietary drug candidates including TRI-611 (oral, brain-penetrant ALK degrader for ALK+ NSCLC in Phase 1/2) and a CCNE1 degrader program for cyclin E1-amplified tumors. Revenue is generated through pharmaceutical licensing collaborations and milestone/royalty arrangements with major pharma partners.

Product overview

Triana Biomedicines is a venture-backed biopharmaceutical company operating a target-first and rational molecular glue discovery platform. The platform identifies small molecules that promote interactions between disease-causing proteins and components of the cell's ubiquitin-proteasome system (E3 ligases), enabling targeted protein degradation of traditionally undruggable disease targets. The current pipeline consists of TRI-611 (lead clinical-stage ALK-targeted molecular glue degrader for ALK+ non-small cell lung cancer in Phase 1/2) and CCNE1 (preclinical cyclin E1 degrader for CCNE1-amplified tumors and HR+/HER2- breast cancer). The company leverages proprietary protein:protein pairing engines, bespoke chemical libraries, and AI/computational tools in its drug discovery efforts.

Differentiator

Problem solved

Functional benefit

Products and services

• TRI-611 Novel oral, small-molecule molecular glue degrader designed to target and degrade ALK fusion proteins in patients with ALK-positive non-small cell lung cancer. Brings ALK and cereblon together through a unique binding mechanism independent of the kinase active site, harnessing the body's innate protein-degradation machinery to selectively eliminate the ALK fusion protein. Brain-penetrant and designed for patients who have failed two or more ALK tyrosine kinase inhibitors. Currently in Phase 1/2 clinical trial.
• CCNE1 Program Preclinical molecular glue degrader program targeting cyclin E1 (CCNE1) for the treatment of CCNE1-amplified tumors and a subset of HR+/HER2- breast cancers. Harnesses the cell's protein degradation machinery to substantially decrease excess CCNE1 and halt growth of CCNE1-dependent tumor cells. Designed to address limited treatment options for CCNE1-amplified tumors and resistance to CDK4/6 inhibitors in HR+/HER2- breast cancer.
• Molecular Glue Discovery Platform Target-first and rational molecular glue discovery platform that evaluates and prioritizes over 600 known E3 ubiquitin ligases and their disease-relevant targets. Powered by high-resolution structural insights, state-of-the-art AI and computational tools, and bespoke chemical libraries to identify small molecules promoting protein-protein interactions for targeted protein degradation. Licensed to pharmaceutical partners (Pfizer, Johnson & Johnson) for molecular glue discovery collaborations.

Quantifiable outcome

• TRI-611 received FDA Fast Track designation for ALK+ NSCLC patients who have failed two or more ALK TKIs (March 2026)
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Johnson & Johnson (Janssen Pharmaceutica NV)coreStrategic or Co-development Partner · 6 January 2026TRIANA entered into a research collaboration with Johnson & Johnson to advance the discovery of important molecular glue targets in oncology. The collaboration applies TRIANA's proprietary molecular glue discovery platform to targets that have been inadequately targeted or considered undruggable.
• PfizercoreStrategic or Co-development Partner · 15 October 2024TRIANA entered into a strategic collaboration and licensing agreement with Pfizer to discover novel molecular glue degraders for multiple targets across various disease areas including oncology. TRIANA received a $49 million upfront payment and is eligible for potential future milestone payments exceeding $1.5 billion plus tiered royalties. TRIANA leads discovery and identification of development candidates; Pfizer has exclusive option for exclusive license to pursue further preclinical and clinical development.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arvinas: Pioneer in targeted protein degradation using PROTACs and molecular glues, with clinical-stage oncology assets (ARV-471, ARV-110). Directly comparable as a TPD-focused biotech with a similar platform approach to tackling previously undruggable targets in oncology.
• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders with a proprietary Pegasus discovery platform. Directly comparable to Triana's molecular glue approach, with multiple programs in oncology and immunology and major pharma partnerships (Vertex, Sanofi).
• Monte Rosa Therapeutics: Clinical-stage biotech focused on molecular glue degraders for cancer and other diseases, with lead assets targeting GSPT1 and NEK7. Direct competitor in molecular glue discovery with a similar platform-based approach and Novartis collaboration.
• C4 Therapeutics: Clinical-stage biotech developing small molecule degraders including the TORPEDO platform for targeted protein degradation. Direct competitor with clinical-stage assets in oncology and partnerships with major pharma including Biogen and Roche.
• Nurix Therapeutics: Clinical-stage biotech developing targeted protein degradation therapies using ligase modulators. Direct competitor with DELigase platform and clinical assets including NX-2127 and NX-5948, plus major pharma partnerships with Gilead, Pfizer, and Sanofi.
• Fog Pharma: Private biotech developing cell-penetrating miniproteins (CPMPs) for cancer, with a platform approach to challenging undruggable targets. Comparable as a platform-based oncology company tackling similar target classes where Triana's VP of Medicinal Chemistry previously served as Head of Medicinal Chemistry.
• Amphista Therapeutics: Private biotech developing next-generation targeted protein degradation therapies with a focus on novel mechanisms beyond cereblon. Comparable platform-based TPD approach with a major pharma partnership with Bristol Myers Squibb valued at over $2B.
• Neomorph: Private biotech focused on discovering molecular glue degraders for undruggable targets in oncology and other diseases. Direct competitor with an AbbVie partnership for molecular glue discovery and significant venture backing from Bain Capital Life Sciences.

Emerging players

• Lycia Therapeutics: Private biotech developing LYTACs (lysosomal targeting chimeras) for extracellular protein degradation. Adjacent technology platform addressing the similar undruggable target opportunity through a different mechanism, with backing from founding investor Versant Ventures.

Broad incumbents

• Bristol Myers Squibb: Large pharmaceutical company with major targeted protein degradation efforts, including a $2B+ partnership with Amphista Therapeutics and active internal TPD research programs. Operates broadly across oncology including protein degradation research and is a potential strategic acquirer of platform-based TPD companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Triana_Bio
• LinkedInlinkedin.com/company/trianabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triana Biomedicines